Home / Healthcare / ViroMed Co., Ltd. - Product Pipeline Review - 2015

ViroMed Co., Ltd. - Product Pipeline Review - 2015

Published: Aug 2015 | No Of Pages: 27 | Published By: Global Markets Direct

ViroMed Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'ViroMed Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the ViroMed Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ViroMed Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ViroMed Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ViroMed Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the ViroMed Co., Ltd.'s pipeline products

Reasons to buy

- Evaluate ViroMed Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ViroMed Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ViroMed Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ViroMed Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ViroMed Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ViroMed Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
ViroMed Co., Ltd. Snapshot 4
ViroMed Co., Ltd. Overview 4
Key Information 4
Key Facts 4
ViroMed Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
ViroMed Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
ViroMed Co., Ltd. - Pipeline Products Glance 11
ViroMed Co., Ltd. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
ViroMed Co., Ltd. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
ViroMed Co., Ltd. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
ViroMed Co., Ltd. - Drug Profiles 15
VM-202 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
VM-206 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
PEG-VM501 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ViroMed Co., Ltd. - Pipeline Analysis 19
ViroMed Co., Ltd. - Pipeline Products by Target 19
ViroMed Co., Ltd. - Pipeline Products by Route of Administration 20
ViroMed Co., Ltd. - Pipeline Products by Molecule Type 21
ViroMed Co., Ltd. - Pipeline Products by Mechanism of Action 22
ViroMed Co., Ltd. - Recent Pipeline Updates 23
ViroMed Co., Ltd. - Dormant Projects 24
ViroMed Co., Ltd. - Locations And Subsidiaries 25
Head Office 25
Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 26
Disclaimer 27

ViroMed Co., Ltd., Key Information 4
ViroMed Co., Ltd., Key Facts 4
ViroMed Co., Ltd. - Pipeline by Indication, 2015 6
ViroMed Co., Ltd. - Pipeline by Stage of Development, 2015 7
ViroMed Co., Ltd. - Monotherapy Products in Pipeline, 2015 8
ViroMed Co., Ltd. - Partnered Products in Pipeline, 2015 9
ViroMed Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015 10
ViroMed Co., Ltd. - Phase III, 2015 11
ViroMed Co., Ltd. - Phase II, 2015 12
ViroMed Co., Ltd. - Phase I, 2015 13
ViroMed Co., Ltd. - Preclinical, 2015 14
ViroMed Co., Ltd. - Pipeline by Target, 2015 19
ViroMed Co., Ltd. - Pipeline by Route of Administration, 2015 20
ViroMed Co., Ltd. - Pipeline by Molecule Type, 2015 21
ViroMed Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 22
ViroMed Co., Ltd. - Recent Pipeline Updates, 2015 23
ViroMed Co., Ltd. - Dormant Developmental Projects,2015 24

ViroMed Co., Ltd. - Pipeline by Top 10 Indication, 2015 6
ViroMed Co., Ltd. - Pipeline by Stage of Development, 2015 7
ViroMed Co., Ltd. - Monotherapy Products in Pipeline, 2015 8
ViroMed Co., Ltd. - Pipeline by Top 10 Target, 2015 19
ViroMed Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015 20
ViroMed Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 21
ViroMed Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 22

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +